Table 1. Summary of Efficacy and Safety Findings Across Included Studies

This table summarizes the key evidence from recent clinical studies on the use of Dupilumab for CSU. It demonstrates findings across various study designs, from case reports to randomized controlled trials, highlighting consistent trends in both efficacy and safety. The data show promising remission rates and symptom control, particularly for patients refractory to other therapies, while indicating a generally favorable safety profile with manageable side effects.